As per the research report, the North America Ophthalmic Drugs market size is valued at around USD 11.62 billion in 2020. It is expected to grow at a CAGR of 4.7% to reach USD 14.62 billion by 2025. It captures 35% of the global market.
Y-O-Y growth in the incidence of eye-related diseases such as macular degeneration and diabetic retinopathy among the growing aging population is a crucial factor driving the ophthalmic drugs market in North America. Increasing cases for glaucoma and dry eyes, rising awareness levels, new medical requirements, and growing cataract in people are considered to fuel the market growth in the coming years. The number of people suffering from diabetic retinopathy in the U.S. is expected to increase from 7.7 million in 2010 to 9.2 million in 2020, which is a positive sign of market growth in this region.
Side-effects associated with ophthalmic drugs and the long-gestation period during the time of advancing the new drugs are significant challenges to the market. Moreover, the high cost of these drugs is also a considerable factor obstructing the market.
This research report on the North America Ophthalmic Drugs Market has been segmented and sub-segmented into the following categories:
Regionally, North America captures the largest share globally due to higher market penetration by the US.
The United States is to lead the market in the region with the largest share of the period. Increasing epitomes of eye-related diseases and resultant vision impairment, which surge the market growth during the period. Numerous approvals of advanced new products and techniques, flourishing patient population who need long-term treatment, are to garnish the market growth during the forecast period. Moreover, the increasing requirement for ophthalmic drugs, most people with vision impairments, which cause uncorrected refractive errors and cataracts in people above 50 years and above, also lifts the market in the ophthalmic drugs market of the North America region.
Canada is projected to have rapid growth in the market during the forecast frame time. This country's evolution is attributed to increasing concentration on research and development activities to enhance innovative treatment, and the existence of key players in the market is to boost the market.
Companies playing a dominant role in the North America Ophthalmic Drugs Market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic Class
5.1.1 Introduction
5.1.2 Anti-inflammatory Drugs
5.1.2.1 Nonsteroidal Anti-inflammatory Drugs
5.1.2.2 Steroids
5.1.3 Anti-infective Drugs
5.1.3.1 Anti-fungal Drugs
5.1.3.2 Anti-bacterial Drugs
5.1.3.3 Others
5.1.4 Anti-glaucoma Drugs
5.1.4.1 Alpha Agonist
5.1.4.2 Beta Blockers
5.1.4.3 Prostaglandin Analogs
5.1.4.4 Combined Medication
5.1.4.5 Others
5.1.5 Anti-allergy Drugs
5.1.6 Anti-VEGF Agents
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class
5.1.9 Market Attractiveness Analysis, By Therapeutic Class
5.1.10 Market Share Analysis, By Therapeutic Class
5.2 Product Type
5.2.1 Introduction
5.2.2 Prescription Drugs
5.2.3 Over-the-Counter Drugs
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Online Pharmacies
5.3.4 Independent Pharmacies & Drug Stores
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
5.4 Disease Indications
5.4.1 Introduction
5.4.2 Dry Eye
5.4.3 Glaucoma
5.4.4 Infection/Inflammation
5.4.5 Retinal Disorders
5.4.5.1 Wet Age-related Macular Degeneration
5.4.5.2 Dry Age-related Macular Degeneration
5.4.5.3 Diabetic Retinopathy
5.4.5.4 Others
5.4.6 Allergy
5.4.7 Uveitis
5.4.8 Others
5.4.9 Y-o-Y Growth Analysis, By Disease Indications
5.4.10 Market Attractiveness Analysis, By Disease Indications
5.4.11 Market Share Analysis, By Disease Indications
5.5 Dosage Form
5.5.1 Introduction
5.5.2 Liquid Ophthalmic Drug Forms
5.5.3 Solid Ophthalmic Drug Forms
5.5.4 Semisolid Ophthalmic Drug Forms
5.5.5 Multicompartment Drug Delivery Systems
5.5.6 Other Ophthalmic Drug Forms
5.5.7 Y-o-Y Growth Analysis, By Dosage Form
5.5.8 Market Attractiveness Analysis, By Dosage Form
5.5.9 Market Share Analysis, By Dosage Form
5.6 Technology
5.6.1 Introduction
5.6.2 Biologics
5.6.3 Cell Therapy
5.6.4 Gene Therapy
5.6.5 Drug Delivery
5.6.6 Small molecule
5.6.7 Others
5.6.8 Y-o-Y Growth Analysis, By Technology
5.6.9 Market Attractiveness Analysis, By Technology
5.6.10 Market Share Analysis, By Technology
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutic Class
6.1.3.3 By Product Type
6.1.3.4 By Distribution Channel
6.1.3.5 By Disease Indication
6.1.3.6 By Dosage Form
6.1.3.7 By Technology
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutic Class
6.1.4.3 By Product Type
6.1.4.4 By Distribution Channel
6.1.4.5 By Disease Indication
6.1.4.6 By Dosage Form
6.1.4.7 By Technology
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutic Class
6.1.5.3 By Product Type
6.1.5.4 By Distribution Channel
6.1.5.5 By Disease Indication
6.1.5.6 By Dosage Form
6.1.5.7 By Technology
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Medical Optics, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Carl-Zeiss AG
8.3 Ellex Medical Lasers Ltd.
8.4 Essilor International S.A.
8.5 Hoya Corporation
8.6 Insight Vision Inc.
8.7 Nidek Co.Ltd
8.8 Novagali Pharma S A
8.9 Topcon Corporation
8.10 Ziemer Ophthalmic Systems AG.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
